"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 5 | 4 | 9 |
| 2006 | 1 | 8 | 9 |
| 2007 | 2 | 4 | 6 |
| 2008 | 5 | 2 | 7 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 5 | 5 |
| 2011 | 1 | 6 | 7 |
| 2012 | 4 | 6 | 10 |
| 2013 | 3 | 8 | 11 |
| 2014 | 2 | 6 | 8 |
| 2015 | 4 | 9 | 13 |
| 2016 | 1 | 10 | 11 |
| 2017 | 4 | 10 | 14 |
| 2018 | 6 | 10 | 16 |
| 2019 | 9 | 11 | 20 |
| 2020 | 4 | 11 | 15 |
| 2021 | 6 | 15 | 21 |
| 2022 | 3 | 13 | 16 |
| 2023 | 4 | 20 | 24 |
| 2024 | 11 | 9 | 20 |
| 2025 | 9 | 10 | 19 |
| 2026 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Malignant peripheral nerve sheath tumors: a report from Children's Oncology Group study ARST0332. J Natl Cancer Inst. 2026 May 01; 118(5):829-838.
-
Total neoadjuvant therapy for rectal cancer: Implications for subsequent liver metastases and chemotherapy-associated liver injury. Surgery. 2026 Jun; 194:110179.
-
Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332. Pediatr Blood Cancer. 2026 May; 73(5):e70228.
-
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 05 10; 44(14):1283-1295.
-
Shifting Paradigm: Utilization and Outcomes with Neoadjuvant Chemotherapy for cT4 and cN2 Colon Cancers. Ann Surg Oncol. 2026 May; 33(5):3849-3860.
-
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030). J Natl Cancer Inst. 2026 Jan 01; 118(1):141-149.
-
Does neoadjuvant systemic therapy in clinical T1-2 N0 human epidermal growth factor receptor 2-positive breast cancer increase the extent of axillary surgery? Surgery. 2026 Mar; 191:109907.
-
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations. Eur Urol Focus. 2026 Jan; 12(1):16-18.
-
Improved liver transplant outcomes for patients with hilar cholangiocarcinoma following implementation of the MMAT-3 policy. Liver Transpl. 2026 Jun 01; 32(6):823-829.
-
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Na?ve and Longitudinal Samples during Neoadjuvant Chemotherapy. Cancer Res. 2025 Nov 03; 85(21):4062-4080.